A phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma.

被引：0
|
作者：
Smrekar, M
Buller, RE
Haba, P
Visser, C
Rose, PG
机构：
[1] Hillcrest Hosp, Mayfield Hts, OH USA
[2] GlaxoSmithKline, Philadelphia, PA USA
[3] Metrohlth Med Ctr, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5147
引用
收藏
页码：485S / 485S
页数：1
相关论文
共 50 条
  • [21] Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Chelariu-Raicu, Anca
    Levenback, Charles F.
    Slomovitz, Brian M.
    Bodurka, Diane C.
    Gershenson, David Marc
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC)
    McGonigle, K. F.
    Muntz, H. G.
    Vuky, J. L.
    Paley, P. J.
    Veljovich, D. S.
    Gray, H. J.
    Malpass, T. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian or primary peritoneal cancer (OC)
    McGonigle, K. F.
    Muntz, H. G.
    Vuky, J.
    Paley, P. J.
    Veljovich, D. S.
    Gray, H. J.
    Malpass, T. W.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (02) : 374 - 374
  • [24] PHASE I STUDY OF THE EORTC-GCG ON PAZOPANIB WITH WEEKLY PACLITAXEL AND CARBOPLATIN IN PLATINUM-RESISTANT OVARIAN CARCINOMA
    Vergote, I.
    Boere, I.
    Casado, A.
    Coens, C.
    Shash, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 475 - 476
  • [25] A phase 3 trial of weekly farletuzumab combined with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse
    Weil, Susan C.
    Jenkins, Michele
    Hoffman, Kimberly
    CANCER RESEARCH, 2012, 72
  • [26] Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study
    Dominique Koensgen
    Dirk Stengel
    Antje Belau
    Peter Klare
    Guelten Oskay-Oezcelik
    Thomas Steck
    Oumar Camara
    Alexander Mustea
    Harald Sommer
    Alexandra Coumbos
    Thomas Bogenrieder
    Werner Lichtenegger
    Jalid Sehouli
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 393 - 400
  • [27] Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study
    Koensgen, Dominique
    Stengel, Dirk
    Belau, Antje
    Klare, Peter
    Oskay-Oezcelik, Guelten
    Steck, Thomas
    Camara, Oumar
    Mustea, Alexander
    Sommer, Harald
    Coumbos, Alexandra
    Bogenrieder, Thomas
    Lichtenegger, Werner
    Sehouli, Jalid
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 393 - 400
  • [28] A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma
    Larry E. Puls
    Bunny Phillips
    Chris Schammel
    James E. Hunter
    David Griffin
    Medical Oncology, 2010, 27 : 368 - 372
  • [29] Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer
    Aghajanian, C
    Dizon, DS
    Sabbatini, P
    Raizer, JJ
    Dupont, J
    Spriggs, DR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5943 - 5949
  • [30] A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma
    Puls, Larry E.
    Phillips, Bunny
    Schammel, Chris
    Hunter, James E.
    Griffin, David
    MEDICAL ONCOLOGY, 2010, 27 (02) : 368 - 372
12345